{"id":"NCT01142726","sponsor":"Bristol-Myers Squibb","briefTitle":"Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis","officialTitle":"A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2013-09","completion":"2014-10","firstPosted":"2010-06-11","resultsPosted":"2014-10-17","lastUpdate":"2016-01-14"},"enrollment":511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Abatacept","otherNames":["Orencia","BMS 188667"]},{"type":"DRUG","name":"Methotrexate","otherNames":["Rheumatrex"]},{"type":"DRUG","name":"Abatacept placebo","otherNames":[]},{"type":"DRUG","name":"Methotrexate placebo","otherNames":[]}],"arms":[{"label":"Abatacept, 125 mg, plus methotrexate, 2.5 mg","type":"ACTIVE_COMPARATOR"},{"label":"Methotrexate, 2.5 mg, plus abatacept placebo","type":"ACTIVE_COMPARATOR"},{"label":"Abatacept, 125 mg, plus methotrexate placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission following 6 months of drug withdrawal.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18","timeFrame":"Randomization to Months 12 and 18","effectByArm":[{"arm":"Abatacept, 125 mg, Plus Methotrexate, 2.5 mg","deltaMin":60.9,"sd":null},{"arm":"Methotrexate, 2.5 mg, Plus Abatacept Placebo","deltaMin":45.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.010"},{"comp":"OG000 vs OG001","p":"0.045"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":8},"locations":{"siteCount":73,"countries":["United States","Australia","Belgium","Canada","Denmark","Finland","France","Germany","Italy","Mexico","Poland","Russia","South Africa","South Korea","Sweden"]},"refs":{"pmids":["35172859","31819995","31278695","30997151","30341453","26865601","25367713"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":119},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Nausea","Bronchitis"]}}